Strategic Acquisition Adamas Pharmaceuticals was acquired by Supernus Pharmaceuticals in 2021 for approximately $400 million, indicating a strong market position and potential cross-selling opportunities for neurological therapies within Supernus's expanded portfolio.

Focus on Neurology The company specializes in neurological diseases, particularly Parkinson's disease, with recent FDA approvals and targeted campaigns, creating opportunities to introduce complementary or enhanced treatments to neurologists and movement disorder specialists.

Innovative Marketing Recent initiatives like the Picture More TimeSM campaign demonstrate a commitment to disease education and patient engagement, which can be leveraged to build relationships with patient advocacy groups and healthcare providers.

Market Expansion With a revenue range of $50M to $100M and an active portfolio of therapies, Adamas presents sales prospects for expanding its reach within neurological treatment centers, specialty pharmacies, and neurology-focused clinics.

Partnership & Research Collaborations with foundations such as the Davis Phinney Foundation reflect an openness to partnerships that support patient advocacy and research initiatives, opening avenues for joint educational programs and targeted outreach campaigns.